Pharma Giants Pull Back On AAV Research: What’s Next For The Gene Therapy Space?

Pharma giants pull back on AAV gene therapy: What’s the next big move?

Biopharmas have been scaling back on AAV research for sometime now. Find out why and what's on the horizon for drug delivery methods. The post Pharma giants pull back on AAV research: what’s next for the gene therapy space? appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpt…

Pharma Giants Pull Back On AAV Research: What’s Next For The Gene Therapy Space?

Newsletter Signup – Under Article / In Page “*” indicates required fields Once hailed as the solution to delivering gene therapies, adeno-associated virus (AAV) vectors have seen their star dim in recent years. Initially touted for its potential to treat a number of genetic disorders, the dwindle in research has now become apparent. The latest biopharma to scale back on AAV research is Vertex Pharmaceuticals, in a blow to the technological space…